Skip to content

Efficacy of Fecal Microbiota Transplantation (FMT) in Irritable Bowel Syndrome (IBS)

Efficacy of Fecal Microbiota Transplantation (FMT) in Irritable Bowel Syndrome (IBS): A Randomized, Placebo-controlled, Double-blind Study

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06201182
Enrollment
45
Registered
2024-01-11
Start date
2020-08-19
Completion date
2024-08-19
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable Bowel Syndrome

Keywords

Fecal microbiota transplantation

Brief summary

The goal of this clinical trial is to determine efficacy of FMT via rectal enema and encapsulated FMT in patients with IBS in Thailand. The main question it aims to answer is: • Does FMT provide better efficacy than placebo in IBS patients? Participants will be randomized into 3 groups: * In placebo group, patients will receive placebo capsules and placebo via enema. * In enema group, patients will receive placebo capsules and FMT via rectal enema. * In capsule group, patients will receive FMT capsules and placebo via rectal enema. Researchers will compare FMT and placebo group to see if using FMT provides better efficacy for IBS patients than placebo. Moreover, researchers will compare efficacy of FMT capsules and FMT via rectal enema in IBS patients.

Detailed description

Irritable bowel syndrome (IBS) is a common functional bowel disorder defined by recurrent abdominal pain related to defecation or a change in bowel habit (1). Pathogenic mechanisms of IBS include gut microbial dysbiosis, low-grade mucosal inflammation, increased gut permeability, and altered gut-brain interaction (2). Dysbiosis is an imbalance of gut microbiota which can contribute to IBS. Emerging treatment approach for IBS aims to correct dysbiosis by modulation of intestinal microbiota (3). Fecal microbiota transplantation (FMT) is an administration of feces from a healthy donor to the gastrointestinal tract of a recipient in order to restore balanced microbial flora (4). Correcting gut dysbiosis might be another target to improve IBS symptoms. Some previous randomized controlled trials demonstrated that FMT could provide clinical response in patients with IBS (5-7), whereas others reported no different outcome from placebo (8, 9). Most trials delivered FMT via more invasive routes such as colonoscopy or gastroscopy. There were few studies using less invasive methods, e.g., oral FMT capsules and FMT via rectal enema. Less invasive routes of FMT administration are needed to be evaluated so as to reduce risk and cost of endoscopy. This study aimed to determine efficacy of FMT via rectal enema and encapsulated FMT compared with placebo in IBS patients in Thailand.

Interventions

DRUGFMT via rectal enema

50 grams of FMT via rectal enema

FMT capsules given twice daily for 2 consecutive days

DRUGPlacebo via rectal enema

Placebo via rectal enema

DRUGPlacebo capsules

Placebo capsules given twice daily for 2 consecutive days

Sponsors

Thammasat University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Intervention model description

Patients will be randomized into 3 groups: * In placebo group, patients will receive placebo capsules and placebo via enema. * In enema group, patients will receive placebo capsules and FMT via rectal enema. * In capsule group, patients will receive FMT capsules and placebo via rectal enema.

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Patients aged 18-70 years with IBS diagnosed by Rome IV criteria * Patients who can provide written informed consent.

Exclusion criteria

* Pregnant or breastfeeding women * Severe comorbidities: chronic kidney disease (GFR\<15 ml/min), cirrhosis, cancer, etc. * Fecal incontinence * Immunocompromised patients * Taking probiotic, or fermented food * Discontinue medication for IBS \<1 month prior to study inclusion

Design outcomes

Primary

MeasureTime frameDescription
The proportion of responders4 weeks, 12 weeksResponse is defined as a decrease in IBS-symptom severity score (IBS-SSS) more than 50 points from baseline.

Secondary

MeasureTime frameDescription
Quality of life score4 weeks, 12 weeksQuality of life score will be assessed in both FMT and placebo groups
Adverse event4 weeks, 12 weeksRecord adverse events during and after treatment
Changes in microbiota diversity before and after FMT4 weeksEvaluate changes in microbiota diversity before and after FMT

Countries

Thailand

Contacts

Primary ContactNatsuda Aumpan, MD
aumpan.natsuda@gmail.com+66870494808
Backup ContactRatha-korn Vilaichone, MD, PhD
vilaichone@hotmail.co.th+66891044488

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026